Tuberculosis drug resistance: A global threat
Tuberculosis drug resistance: A global threat
复制标题
DOI：
10.1086/344657
复制
发表时间：
2003-01-15
影响因子：
11.8
通讯作者：
Chaisson, RE
中科院分区：
文献类型：
--
作者：
Nachega, JB;Chaisson, RE
自化疗时代开始以来，抗结核药物的耐药性一直是一个问题。20世纪90年代初，在耐多药结核病（MDR-TB）大规模暴发之后，耐药性被认为是一个全球性问题。耐多药结核病现在威胁着欧洲、亚洲、非洲和美洲国家的居民。了解耐药性的分子基础可能有助于新药的开发。耐多药结核病的管理依赖于及时识别和使用分离株至少3种易感药物进行治疗。
Resistance to antituberculosis drugs has been a problem since the era of chemotherapy began. After dramatic outbreaks of multidrug-resistant tuberculosis (MDR-TB) in the early 1990s, resistance became recognized as a global problem. MDR-TB now threatens the inhabitants of countries in Europe, Asia, Africa, and the Americas. An understanding of the molecular basis of drug resistance may contribute to the development of new drugs. Management of MDR-TB relies on prompt recognition and treatment with at least 3 drugs to which an isolate is susceptible.